Update on Clinical Development Study

31 Mar 2023 06:00 CEST

The Clinical Development Study with the Sencell sensor will continue for a few
more weeks.

- We operate complex and pioneering sensor technology and strive to ensure high
quality at all stages of the process. We therefore want to extend the Clinical
Development Study by a few weeks more than previously communicated, says CEO
Joacim Holter.

The sensors we use in the study are handmade in our laboratory in Reutlingen,
Germany. This is of course time-consuming work, due to the small size of the
sensors and our quality focus. In the future, the sensors will of course be
mechanically produced in a streamlined manner.

In February, Lifecare announced that sensors used in a three-day clinical study
continue to work in an in vitro set up. This confirms the expectation of a
sensor longevity that far exceeds the lifetime of existing and commercially
available needle sensors for glucose monitoring. The company reported that
sensors used in a three-day clinical study continue to work in an in vitro set
up, showing an operational longevity for a total of 4 weeks and are still
ongoing. 

This stock exchange announcement was published by Joacim Holter, CEO at Lifecare
AS, on 31.3.23 at 06:00 AM CET.

More information:
Access the news on Oslo Bors NewsWeb site